Citigroup Now Covering Abeona Therapeutics (NASDAQ:ABEO) With $32 Target

Abeona Therapeutics Inc

Abeona Therapeutics Inc. (NASDAQ:ABEO) Sees Price Increase – Up $2.55

Therefore 100% are positive.

In recent action, Abeona Therapeutics Inc. The average 12 month price objective among brokerages that have issued a report on the stock in the past year is $24.00. BidaskClub downgraded Abeona Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 2nd. Out of the analyst recommendations 1 rate Abeona Therapeutics (NASDAQ:ABEO) stock a Buy, 5 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has "Buy" rating given on Tuesday, July 18 by Maxim Group. The original version of this news story can be accessed at https://www.truebluetribune.com/2017/10/12/abeona-therapeutics-inc-abeo-price-target-increased-to-34-00-by-analysts-at-cantor-fitzgerald.html. The firm earned "Buy" rating on Monday, May 15 by Cantor Fitzgerald. On Friday, October 6 the stock rating was maintained by Cantor Fitzgerald with "Buy". The firm earned "Buy" rating on Tuesday, August 11 by TheStreet.

W.W. Grainger, Inc.is a distributor of maintenance, fix and operating (MRO) supplies and other related services and products. The company has market cap of $146.47 billion. Its product pipeline also consists of MuGard and ProdiGard. The Firm operates in four divisions: Property&Casualty Reinsurance, Life&Health Reinsurance, Corporate Solutions and Life Capital.

Six people taken to hospital after attempted NC prison escape
An attempted escape from a North Carolina prison left multiple people injured Thursday, public safety officials said. According to Peter Sengenberger from Sentara Healthcare, six people were taken to Sentara Albemarle Medical Center.

Ratings analysis reveals 33% of Grainger's analysts are positive. The stock hit its twelve month high on 10/11/17, and twelve month low on 12/21/16. They may look to the 50-day or 20-day to get a better grasp of what is going on with the stock in the near-term. GWW was included in 3 notes of analysts from August 26, 2016.

10/9/2017-HC Wainwright Reiterated Rating of Buy.

The top 5 institutional holders, in ascending order, are as follows: KNOLL CAPITAL MANAGEMENT, LP with 2.36 million shares, ADAGE CAPITAL PARTNERS GP, L.L.C. with 1.95 million shares, BAKER BROS. Coho Partners Ltd. owns 693,866 shares or 3.13% of their U.S. portfolio. It tells investors how well a company is turning their capital into profits. The Japan-based Mu Investments Co. The percentage of shares being held by the company management was 1.6% while institutional stake was 0%. ADVISORS LP with 1.68 million shares, BLACKROCK INC. with 1.23 million shares, and VANGUARD GROUP INC with 1.08 million shares. The total number of shares traded in the last 12 months is 100,000. This key information was disclosed in a research report on 11 October.

Paris to Ban Gas-Powered Vehicles a Decade Ahead of Schedule
Current owners of diesel cars will be allowed to continue to drive their vehicles in the city, the reports have suggested. Paris officials have taken to making public transportation free on days when pollution levels are especially high.

The Earnings to Price yield of Abeona Therapeutics Inc.

About 190,703 shares traded. Abeona Therapeutics Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Wider Todd has acquired 5,000 shares of Abeona Therapeutics Inc. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., launched on June 22, 1989, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. This company shares are 15.29% off its target price of $23 and the current market capitalization stands at $755.91M. A negative earnings surprise will usually result in a decline in share price. It is also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

President Trump Nominates Deputy Chief Of Staff To Lead DHS
President Donald Trump nominated White House aide Kirstjen Nielsen to be the next secretary of Homeland Security on Wednesday. That includes restricting access to the Oval Office and streamlining the flow of information to the president.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Latest News